Mannkind CORP (MNKD) — SEC Filings

Q: What are the key financial highlights for Mannkind CORP?

Key financial highlights for Mannkind CORP are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Mannkind CORP?

Key executives at Mannkind CORP are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Mannkind CORP stock?

Risk factors for Mannkind CORP (MNKD) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Mannkind CORP?

Forward-looking statements and predictions from Mannkind CORP are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Mannkind CORP. Recent ARS filing on Apr 7, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Mannkind CORP on SEC EDGAR

Overview

Mannkind CORP (MNKD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K/A filed on Dec 15, 2025: MannKind Corporation filed an amendment (Amendment No. 1) to its Form 8-K on October 7, 2025. This amendment pertains to financial statements and exhibits, with the filing date being December 15, 2025. The company is incorporated in Delaware and its principal executive offices are located at 1 Caspe

Sentiment Summary

Across 28 filings, the sentiment breakdown is: 26 neutral, 2 mixed. The dominant filing sentiment for Mannkind CORP is neutral.

Filing Type Overview

Mannkind CORP (MNKD) has filed 1 ARS, 1 8-K/A, 13 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (28)

ARS Filing — ARS · Apr 7, 2026
MannKind Corp Files 8-K Amendment — 8-K/A · Dec 15, 2025 Risk: low
MannKind Corporation filed an amendment (Amendment No. 1) to its Form 8-K on October 7, 2025. This amendment pertains to financial statements and exhibits, with
8-K Filing — 8-K · Nov 10, 2025
MannKind's Revenue Climbs, But Impairment Hits Q3 Net Income — 10-Q · Nov 5, 2025 Risk: medium
MannKind Corporation reported a mixed financial performance for the three and nine months ended September 30, 2025. Total revenues increased by 17.2% to $82.1 m
MannKind Corp Completes Asset Acquisition — 8-K · Oct 9, 2025 Risk: medium
MannKind Corporation (MNKD) announced on October 7, 2025, the completion of an acquisition of assets. The company also entered into a material definitive agreem
MannKind Corp Files 8-K: Material Definitive Agreement — 8-K · Aug 27, 2025 Risk: medium
On August 24, 2025, MannKind Corporation entered into a material definitive agreement. The filing does not provide specific details about the agreement's nature
MannKind Corp Files 8-K with Material Agreement — 8-K · Aug 25, 2025 Risk: medium
On August 24, 2025, MannKind Corporation entered into a material definitive agreement. The company also made a Regulation FD disclosure and filed financial stat
MannKind's Product Revenue Jumps 25% Amidst Strategic Agreements — 10-Q · Aug 6, 2025 Risk: medium
MannKind Corp (MNKD) reported product revenue of $100.0 million for the six months ended June 30, 2025, compared to $80.0 million for the same period in 2024, r
MannKind Corp Files 8-K on Shareholder Vote Matters — 8-K · May 19, 2025 Risk: low
MannKind Corporation filed an 8-K on May 19, 2025, reporting on a submission of matters to a vote of security holders that occurred on May 14, 2025. The filing
MannKind Corp Reports Director Changes and Compensation Updates — 8-K · May 15, 2025 Risk: medium
On May 9, 2025, MannKind Corporation filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the electi
MannKind Corp Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
MannKind Corporation filed a 10-Q for the period ending March 31, 2025. The filing details financial information, including assets, liabilities, and equity. Spe
MannKind Corp Executive Compensation Details Revealed — DEF 14A · Apr 1, 2025 Risk: medium
MannKind Corp filed its DEF 14A on April 1, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information
MannKind Corp Files 2024 10-K — 10-K · Feb 26, 2025 Risk: medium
MannKind Corporation filed its 10-K for the fiscal year ending December 31, 2024, detailing its financial performance and business operations. The company, inco
MannKind Corp: Executive Changes and Compensation Update — 8-K · Jan 6, 2025 Risk: medium
MannKind Corporation announced on January 2, 2025, changes in its board of directors and executive compensation. Specifically, Michael A. Castagna, Jr. resigned
MannKind Corp Reports Unregistered Equity Sales — 8-K · Dec 18, 2024 Risk: medium
On December 17, 2024, MannKind Corporation filed an 8-K report detailing unregistered sales of equity securities. The filing also noted other events, but specif
MannKind Corp Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
MannKind Corporation filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third qua
MannKind Corp Appoints New Director and CMO — 8-K · Aug 14, 2024 Risk: medium
MannKind Corporation announced on August 13, 2024, changes in its executive and director roles. The company elected Dr. Michael Merz as a new director and appoi
MannKind Corp Files Q2 2024 10-Q — 10-Q · Aug 7, 2024 Risk: medium
MannKind Corporation filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business operations.
MannKind Corp Files 8-K on Shareholder Vote — 8-K · May 16, 2024 Risk: low
MannKind Corporation filed an 8-K on May 16, 2024, reporting on matters submitted to a vote of its security holders on May 15, 2024. The filing details the comp
MannKind Corp Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 8, 2024 Risk: medium
MANNKIND CORP (MNKD) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. MannKind Corporation filed a 10-Q report for the period ending March 31, 2024.
MannKind Corp Files Definitive Proxy Statement — DEF 14A · Apr 5, 2024 Risk: low
MANNKIND CORP (MNKD) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. MannKind Corporation filed a Definitive Proxy Statement on April 5, 2024.
MannKind Corp Files 8-K: Other Event — 8-K · Apr 3, 2024 Risk: low
On April 1, 2024, MannKind Corporation (MNKD) filed an 8-K report detailing an "Other Event." The filing does not disclose specific financial figures or signifi
MannKind Appoints Michael A. Castagna as CEO — 8-K · Mar 26, 2024 Risk: medium
MannKind Corporation announced on March 25, 2024, the appointment of Michael A. Castagna as Chief Executive Officer, effective immediately. Castagna, who has be
MannKind Corp Files 2023 Annual Report on Form 10-K — 10-K · Feb 27, 2024 Risk: medium
MANNKIND CORP (MNKD) filed a Annual Report (10-K) with the SEC on February 27, 2024. MannKind Corporation filed its annual report on Form 10-K for the fiscal ye
Vanguard Group Updates MannKind Corp Stake: 420,635 Shares Shared Voting — SC 13G/A · Feb 13, 2024 Risk: low
The Vanguard Group, a major investment firm, filed an amended SC 13G/A on February 13, 2024, disclosing its ownership in MannKind Corp. As of December 29, 2023,
BlackRock Amends MannKind Stake, Maintains Passive Position — SC 13G/A · Jan 25, 2024
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership of MannKind Corp. common stock as of December 31, 2023. This amendment, n
State Street Corp Updates Passive Stake in MannKind Corp — SC 13G/A · Jan 22, 2024
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 22, 2024, indicating its ownership of MannKind Corp's common stock
MannKind Enters Material Definitive Agreement on Dec 27 — 8-K · Jan 2, 2024
MannKind Corporation filed an 8-K on January 2, 2024, reporting an "Entry into a Material Definitive Agreement" on December 27, 2023. This filing indicates that

Risk Profile

Risk Assessment: Of MNKD's 23 recent filings, 0 were flagged as high-risk, 17 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Mannkind CORP's most recent 10-Q filing (Nov 5, 2025):

Revenue: $82.1M
Net Income: $8.0M
Cash Position: $127.4M

Key Executives

Michael A. Castagna, Jr.
Dr. Michael A. Mercali
Steven B. Binder
Dr. Michael Merz
Michael A. Castagna

Industry Context

The pharmaceutical industry, particularly in the diabetes care segment, is characterized by intense competition, significant R&D investment, and stringent regulatory hurdles. Companies like MannKind must navigate patent cliffs, generic competition, and evolving treatment paradigms. The recent merger with scPharmaceuticals indicates a strategy to diversify and strengthen its market position through product acquisition.

Top Tags

amendment (4) · 10-Q (4) · financials (4) · pharmaceuticals (4) · material-agreement (3) · MannKind Corp (3) · institutional-ownership (3) · Revenue Growth (2) · filing (2) · Pharmaceuticals (2)

Key Numbers

Total revenues for Q3 2025: $82.1M — Increased by 17.2% from $70.1M in Q3 2024
Total revenues for nine months ended Sep 30, 2025: $237.0M — Increased by 13.5% from $208.7M in the prior year period
Net income for Q3 2025: $8.0M — Decreased by 30.9% from $11.6M in Q3 2024
Net income for nine months ended Sep 30, 2025: $21.8M — Increased by 8.2% from $20.2M in the prior year period
Impairment of available-for-sale investment: $6.4M — Significant expense in Q3 2025, contributing to net income decrease
Loss on foreign currency transaction: $7.8M — For nine months ended Sep 30, 2025, up from $0.5M in prior year
Cash and cash equivalents: $127.4M — As of Sep 30, 2025, up from $46.3M at Dec 31, 2024
Proceeds from term loan: $75.0M — Contributed to increased cash and cash equivalents
Afrezza commercial product sales for Q3 2025: $18.5M — Increased by 23.0% from $15.0M in Q3 2024
Royalties for Q3 2025: $33.3M — Increased by 24.5% from $27.1M in Q3 2024
SEC File Number: 000-50865 — Identifies the specific filing with the SEC.
IRS Employer Identification No.: 13-3607736 — Tax identification number for the company.
Product Revenue: $100.0M — Increased 25% for the six months ended June 30, 2025, from $80.0M in 2024.
Liability for Sale of Future Royalties: $10.0M — Reported as of June 30, 2025, impacting the company's financial position.
Royalty Liability: $5.0M — Outstanding as of June 30, 2025, requiring future payments.

Related Companies

UTHR

Frequently Asked Questions

What are the latest SEC filings for Mannkind CORP (MNKD)?

Mannkind CORP has 28 recent SEC filings from Jan 2024 to Apr 2026, including 13 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of MNKD filings?

Across 28 filings, the sentiment breakdown is: 26 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Mannkind CORP SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Mannkind CORP (MNKD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Mannkind CORP?

Key financial highlights from Mannkind CORP's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for MNKD?

The investment thesis for MNKD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Mannkind CORP?

Key executives identified across Mannkind CORP's filings include Michael A. Castagna, Jr., Dr. Michael A. Mercali, Steven B. Binder, Dr. Michael Merz, Michael A. Castagna.

What are the main risk factors for Mannkind CORP stock?

Of MNKD's 23 assessed filings, 0 were flagged high-risk, 17 medium-risk, and 6 low-risk.

What are recent predictions and forward guidance from Mannkind CORP?

Forward guidance and predictions for Mannkind CORP are extracted from SEC filings as they are enriched.